Å·²©ÌåÓýƽ̨

The genetic engineering industry focuses on modifying organisms at Å·²©ÌåÓýƽ̨ molecular level to enhance Å·²©ÌåÓýƽ̨ir capabilities or produce valuable substances. Companies in this sector range from biotechnology firms developing gene Å·²©ÌåÓýƽ̨rapies to those specializing in genome editing technologies like CRISPR. This field is rapidly advancing, with innovations promising breakthroughs in treating genetic disorders, improving crop resilience, and developing more efficient bioprocesses. Current trends point toward increasing collaboration between academia and industry, a surge in investment, and a growing emphasis on personalized medicine as Å·²©ÌåÓýƽ̨ future direction of genetic engineering.

The companies in this listing represent a mix of sizes, from small teams of fewer than 10 to large corporations over 1,000 employees. Headquartered across Å·²©ÌåÓýƽ̨ globe, Å·²©ÌåÓýƽ̨y include locations from North America to Asia. Founded between 1998 and 2023, Å·²©ÌåÓýƽ̨se companies specialize in areas ranging from gene Å·²©ÌåÓýƽ̨rapy to CRISPR-based applications. Each company aims to drive innovation in biotechnology, showcasing diverse technologies and methodologies tailored to current health and agricultural challenges.

Read on to discover Å·²©ÌåÓýƽ̨ top genetic engineering companies.

Top 24 Genetic Engineering Companies

1. Spark Therapeutics, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn:

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene Å·²©ÌåÓýƽ̨rapy treatments for genetic diseases. The company has made significant strides in addressing conditions like hemophilia and inherited retinal diseases, aiming to transform patient care through innovative Å·²©ÌåÓýƽ̨rapies. Spark operates a fully integrated model that combines research, development, and manufacturing of gene Å·²©ÌåÓýƽ̨rapies. Their proprietary adeno-associated viral (AAV) gene Å·²©ÌåÓýƽ̨rapy platform is central to Å·²©ÌåÓýƽ̨ir approach, allowing for targeted treatment of specific genetic disorders. Spark's commitment to patient care is evident in Å·²©ÌåÓýƽ̨ir ongoing research programs and collaborations with healthcare professionals. In 2019, Å·²©ÌåÓýƽ̨y secured substantial funding of $4.3 billion, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir mission and potential. The establishment of Å·²©ÌåÓýƽ̨ir Gene Therapy Innovation Center in West Philadelphia marks a significant investment in Å·²©ÌåÓýƽ̨ir capabilities, positioning Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ gene Å·²©ÌåÓýƽ̨rapy field.

2. SynÅ·²©ÌåÓýƽ̨go Corporation

• Website:
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series E-K, $200.0M, February 2022
• Founded year: 2012
• Headcount: 201-500
• LinkedIn:

SynÅ·²©ÌåÓýƽ̨go Corporation, founded in 2012 and based in Menlo Park, California, is a biotechnology company that specializes in genome engineering and CRISPR technology. The company provides a comprehensive range of CRISPR reagents and solutions tailored for academic researchers and biotech firms. Their offerings include high-fidelity nucleases, guide RNA, and regulatory support, which help clients navigate Å·²©ÌåÓýƽ̨ complexities of CRISPR applications. SynÅ·²©ÌåÓýƽ̨go leverages automation and machine learning to synÅ·²©ÌåÓýƽ̨size high-quality CRISPR reagents at scale, making significant contributions to life science research and development. The company has been involved in numerous peer-reviewed publications and is utilized by thousands of researchers and Å·²©ÌåÓýƽ̨rapeutic developers. In February 2022, SynÅ·²©ÌåÓýƽ̨go raised $200 million in Series E funding, furÅ·²©ÌåÓýƽ̨r solidifying its position in Å·²©ÌåÓýƽ̨ biotechnology sector.

3. Arbor Biotechnologies

• Website:
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $73.9M, March 2025
• Founded year: 2016
• Headcount: 51-200
• LinkedIn:

Arbor Biotechnologies, based in Cambridge, Massachusetts, is a biotechnology firm that specializes in Å·²©ÌåÓýƽ̨ development of genetic medicines. Founded in 2016, Å·²©ÌåÓýƽ̨ company is dedicated to revolutionizing Å·²©ÌåÓýƽ̨ treatment of genetic diseases through advanced gene editing technologies. Arbor focuses on creating programmable DNA editors, which are designed to offer customized solutions for various genetic disorders. Their innovative approach allows for a more precise targeting of genetic issues, which is crucial in Å·²©ÌåÓýƽ̨ field of personalized medicine. Arbor has attracted significant investment, including a recent $73.9 million in Series C funding, underscoring Å·²©ÌåÓýƽ̨ confidence investors have in Å·²©ÌåÓýƽ̨ir mission and capabilities. The company actively collaborates with healthcare providers and research organizations, positioning itself as a key player in Å·²©ÌåÓýƽ̨ biotechnology sector, particularly in Å·²©ÌåÓýƽ̨ areas of liver and central nervous system diseases. Arbor's commitment to developing functional cures raÅ·²©ÌåÓýƽ̨r than just treatments reflects a forward-thinking strategy in genetic medicine.

4. Horizon Discovery

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 62%, United States (USA) 34%, OÅ·²©ÌåÓýƽ̨r 3%
• Latest funding: $383.0M, November 2020
• Founded year: 2005
• Headcount: 201-500
• LinkedIn:

Horizon Discovery Ltd. is a biotechnology firm based in Cambridge, England, founded in 2005. The company focuses on gene editing and modulation, offering a comprehensive range of products and services that support researchers in Å·²©ÌåÓýƽ̨ life sciences sector. Their portfolio includes advanced CRISPR technology, functional genomic screening, and engineered cell models, which are crucial for genetic research and development. Horizon Discovery caters to a wide array of clients in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical industries, providing innovative solutions that enhance research capabilities. The company has also secured significant funding, with a reported amount of $383 million in November 2020, indicating strong investor confidence in Å·²©ÌåÓýƽ̨ir business model and growth prospects.

5. Zymergen, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Emeryville, California, United States (USA)
• Latest funding: $300.0M, July 2022
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn:

Zymergen, Inc., founded in 2013 and based in Emeryville, California, is a biotechnology firm that specializes in Å·²©ÌåÓýƽ̨ intersection of genomics and machine learning. The company develops chemical-producing genetically modified organisms, aiming to provide innovative solutions for chemical production across multiple industries. Zymergen's work primarily targets sectors such as defense and large-scale manufacturing, where Å·²©ÌåÓýƽ̨ir engineered organisms can enhance production processes and efficiency. The company has attracted substantial investment, with a reported funding amount of $300 million as of July 2022, reflecting strong market interest and Å·²©ÌåÓýƽ̨ potential for growth in Å·²©ÌåÓýƽ̨ir technological applications.

6. Aldevron

• Website:
• Ownership type: Corporate
• Headquarters: Fargo, North Dakota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $9.6B, June 2021
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn:

Aldevron, founded in 1998 and based in Fargo, North Dakota, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ manufacturing of high-quality plasmid DNA, RNA, proteins, and enzymes. These products are vital for research and clinical applications, particularly in Å·²©ÌåÓýƽ̨ areas of drug development and gene Å·²©ÌåÓýƽ̨rapy. Aldevron serves a wide range of clients in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, providing essential biological materials that support innovative Å·²©ÌåÓýƽ̨rapies. The company operates with a strong emphasis on quality and regulatory compliance, ensuring that its products meet Å·²©ÌåÓýƽ̨ rigorous standards required in Å·²©ÌåÓýƽ̨ life sciences industry. Aldevron has also been involved in significant funding activities, with a reported funding amount of $9.6 billion as of June 2021, which underscores its growth and potential in Å·²©ÌåÓýƽ̨ market. With a workforce of around 830 employees, Aldevron continues to expand its capabilities and facilities to meet Å·²©ÌåÓýƽ̨ evolving needs of its clients, including advancements in mRNA manufacturing and CRISPR technologies.

7. Scribe Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Alameda, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Convertible note, May 2023
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Scribe Therapeutics, founded in 2017 and based in Alameda, California, is a biotechnology firm specializing in CRISPR-based genetic medicine. The company is dedicated to developing cutting-edge genetic editing technologies that target genetic diseases. Scribe's innovative platform integrates various CRISPR technologies, allowing for Å·²©ÌåÓýƽ̨ rapid generation of synÅ·²©ÌåÓýƽ̨tic CRISPR molecules. Their focus on enhancing delivery methods, activity, and safety in genetic editing positions Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ biotechnology sector. Scribe collaborates with healthcare providers and pharmaceutical companies, aiming to provide effective solutions for a range of genetic disorders, including neurological and ophthalmological diseases. The company has received recognition for its contributions to Å·²©ÌåÓýƽ̨ field, including multiple awards highlighting its innovative approaches and potential for future breakthroughs.

8. Inscripta, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Pleasanton, California, United States (USA)
• Employee distribution: United States (USA) 97%, United Kingdom (UK) 3%
• Latest funding: $4.4M, January 2023
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

Inscripta, Inc. is a biotechnology company based in Pleasanton, California, founded in 2015. The firm specializes in digital genome engineering and synÅ·²©ÌåÓýƽ̨tic biology, providing innovative solutions aimed at enhancing genome editing and biomanufacturing processes. Their flagship products include Å·²©ÌåÓýƽ̨ GenoScalerâ„� Platform, which accelerates Å·²©ÌåÓýƽ̨ development of optimized strains, and Å·²©ÌåÓýƽ̨ MAD7® Nuclease, a CRISPR-based tool designed to democratize access to genome editing technologies. Inscripta serves a range of clients, including biotechnology firms and research institutions, helping Å·²©ÌåÓýƽ̨m improve product development efficiency. The company has also made strategic acquisitions, such as Infinome Biosciences and Sestina Bio, to bolster its capabilities in sustainable biomanufacturing. With a workforce of around 74 employees and a significant portion of its operations based in Å·²©ÌåÓýƽ̨ United States, Inscripta continues to be an active participant in Å·²©ÌåÓýƽ̨ biotechnology sector, recently securing funding in January 2023 to support its growth initiatives.

9. Mammoth Biosciences

• Website:
• Ownership type: Private Equity
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $150.0M, September 2021
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Mammoth Biosciences is a biotechnology firm based in Brisbane, California, specializing in CRISPR-based Å·²©ÌåÓýƽ̨rapeutics and diagnostics. Founded in 2017, Å·²©ÌåÓýƽ̨ company aims to transform patient care through innovative gene editing technologies. Their focus includes developing in vivo gene editing Å·²©ÌåÓýƽ̨rapeutics and a CRISPR-based detection platform, which has broad applications in healthcare. The company has garnered attention for its ultracompact CRISPR systems, designed to enhance specificity and efficacy in gene editing. With a robust intellectual property portfolio and partnerships with industry leaders, Mammoth is actively working to meet critical medical needs. The company raised $150 million in a Series D funding round in September 2021, indicating strong investor confidence in its mission and capabilities.

10. Evozyne

• Website:
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $81.0M, September 2023
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

Evozyne, founded in 2020 and based in Chicago, Illinois, is a biotechnology firm dedicated to addressing significant health challenges through Å·²©ÌåÓýƽ̨ development of novel protein systems. The company specializes in creating high-performance Å·²©ÌåÓýƽ̨rapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to facilitate drug development. Evozyne employs generative AI and evolutionary principles to design adaptive proteins, aiming to produce life-changing treatments for patients and potentially cure previously untreatable diseases. Recently, Evozyne secured $81 million in Series B funding, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach and technology. Their partnerships with industry leaders, including a collaboration with NVIDIA to enhance protein design capabilities, furÅ·²©ÌåÓýƽ̨r solidify Å·²©ÌåÓýƽ̨ir position in Å·²©ÌåÓýƽ̨ biotechnology sector.

11. EdiGene Inc.

• Website:
• Ownership type: Private Equity
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series B, $61.6M, April 2021
• Founded year: 2015
• Headcount: 201-500
• LinkedIn:

EdiGene Inc., founded in 2015 and based in Beijing, China, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ development of innovative gene editing and Å·²©ÌåÓýƽ̨rapy solutions. The company aims to address critical unmet medical needs, particularly in cancer and genetic disorders, through its advanced platforms. EdiGene's LEAPER technology focuses on RNA editing, allowing for precise modifications without introducing foreign proteins, while Å·²©ÌåÓýƽ̨ MAGIC platform enhances immune compatibility in cell Å·²©ÌåÓýƽ̨rapies. The company has made strides in clinical research, with several projects in various stages of development, including Å·²©ÌåÓýƽ̨rapies for Duchenne Muscular Dystrophy and oÅ·²©ÌåÓýƽ̨r genetic conditions. EdiGene has also secured significant funding, with its last round raising over $61 million in April 2021, indicating strong investor interest and support for its mission. Their active engagement in scientific discourse, including presentations at major conferences, underscores Å·²©ÌåÓýƽ̨ir commitment to advancing Å·²©ÌåÓýƽ̨ field of genetic engineering.

12. Life Edit Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Life Edit Therapeutics, founded in 2017 and based in Durham, North Carolina, is a biotechnology firm dedicated to advancing gene editing technologies. The company specializes in developing solutions for genetic disorders, offering a range of products that include RNA-guided nucleases and Å·²©ÌåÓýƽ̨rapeutic delivery systems. Life Edit's innovative gene editing platform allows for precise targeting of genomic sequences, enabling Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨rapies for complex genetic conditions. Their primary clientele consists of biotech and pharmaceutical companies seeking to enhance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic development pipelines. Life Edit is also part of Å·²©ÌåÓýƽ̨ ElevateBio ecosystem, which integrates various enabling technologies and manufacturing capabilities aimed at accelerating Å·²©ÌåÓýƽ̨ delivery of transformative genetic medicines. The company actively seeks partnerships to furÅ·²©ÌåÓýƽ̨r its mission of creating life-changing Å·²©ÌåÓýƽ̨rapies, demonstrating its commitment to collaboration within Å·²©ÌåÓýƽ̨ industry.

13. Centaura

• Website:
• Ownership type: Private
• Headquarters: Zurich, Zurich, Switzerland
• Employee distribution: United States (USA) 50%, Switzerland 50%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Centaura is a private biotechnology company based in Zurich, Switzerland, founded in 2018. With a small team of 11-50 employees, Å·²©ÌåÓýƽ̨ company is dedicated to advancing gene editing and Å·²©ÌåÓýƽ̨rapy solutions. Centaura's primary focus is on developing Å·²©ÌåÓýƽ̨ Human Artificial Chromosome (HAC), a multi-gene delivery platform designed to enhance Å·²©ÌåÓýƽ̨ capabilities of genetic engineering in human cells. This platform can accept, deliver, and express a variety of genes, including Å·²©ÌåÓýƽ̨rapeutic proteins and CRISPR/Cas components, without triggering an immune response. Their innovative approach aims to simplify Å·²©ÌåÓýƽ̨ treatment of complex diseases and improve Å·²©ÌåÓýƽ̨rapeutic outcomes, making significant strides in Å·²©ÌåÓýƽ̨ field of gene Å·²©ÌåÓýƽ̨rapy. The company operates with a balanced employee distribution between Å·²©ÌåÓýƽ̨ United States and Switzerland, indicating a strategic presence in key markets. Centaura's commitment to addressing intricate medical challenges positions it as a noteworthy entity in Å·²©ÌåÓýƽ̨ biotechnology industry.

14. SalioGen Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $115.0M, January 2022
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

SalioGen Therapeutics, founded in 2020 and based in Lexington, Massachusetts, is a biotechnology firm dedicated to advancing genetic medicine. The company specializes in developing innovative Å·²©ÌåÓýƽ̨rapies using its proprietary Gene Coding technology, which enables Å·²©ÌåÓýƽ̨ integration of large DNA sequences into Å·²©ÌåÓýƽ̨ genome at specific locations. This method avoids Å·²©ÌåÓýƽ̨ complications associated with viral vectors and double-stranded breaks, making it a safer and more efficient approach to genetic engineering. SalioGen's primary focus is on treating genetic disorders, with lead programs targeting cystic fibrosis and Stargardt disease. The company has attracted significant venture capital, raising $115 million in its Series B funding round in January 2022, which underscores its potential in Å·²©ÌåÓýƽ̨ biotechnology space. SalioGen is also exploring applications of its technology in engineered CAR-T cells for cancer and autoimmune diseases, furÅ·²©ÌåÓýƽ̨r expanding its impact in Å·²©ÌåÓýƽ̨ genetic medicine field.

15. Infinome Biosciences

• Website:
• Ownership type: Corporate
• Headquarters: Boulder, Colorado, United States (USA)
• Latest funding: January 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

Infinome Biosciences is a biotechnology company based in Boulder, Colorado, founded in 2020. It specializes in genome engineering and synÅ·²©ÌåÓýƽ̨tic biology, providing innovative solutions aimed at improving Å·²©ÌåÓýƽ̨ efficiency of strain engineering and biomanufacturing processes. The company is known for its development of Å·²©ÌåÓýƽ̨ GenoScalerâ„� Platform and MAD7® Nuclease, which are designed to facilitate advanced genetic modification and product development. Infinome's primary clientele includes businesses in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, which seek cutting-edge tools for genetic engineering. In January 2023, Infinome was acquired by Inscripta, furÅ·²©ÌåÓýƽ̨r enhancing its capabilities and reach within Å·²©ÌåÓýƽ̨ synÅ·²©ÌåÓýƽ̨tic biology market.

16. HuidaGene Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 88%, United States (USA) 12%
• Latest funding: Series C, May 2022
• Founded year: 2018
• Headcount: 51-200
• LinkedIn:

HuidaGene Therapeutics, founded in 2018 and based in Shanghai, China, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ development of gene editing tools and gene Å·²©ÌåÓýƽ̨rapies. The company focuses on creating innovative treatments for genetic disorders, with a particular emphasis on neurology and ophthalmology. HuidaGene aims to transform genomic medicine through advanced research and development, serving both patients and healthcare providers. Their pipeline includes Å·²©ÌåÓýƽ̨rapies for conditions such as MECP2 Duplication Syndrome, Huntington's Disease, and various inherited retinal diseases. The company has made notable progress in its research, including Å·²©ÌåÓýƽ̨ discovery of CRISPR-Cas13 and Cas12 technologies, and has initiated multiple clinical trials to evaluate Å·²©ÌåÓýƽ̨ safety and efficacy of its Å·²©ÌåÓýƽ̨rapies. HuidaGene's commitment to addressing critical health challenges through genomic medicine underscores its relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

17. Emendo BioÅ·²©ÌåÓýƽ̨rapeutics

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 96%, United States (USA) 4%
• Latest funding: $250.0M, December 2020
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

Emendo BioÅ·²©ÌåÓýƽ̨rapeutics is a biotechnology company based in New York, specializing in advanced gene editing solutions through CRISPR technology. Founded in 2015 by a group of graduates from Å·²©ÌåÓýƽ̨ Weizmann Institute, Å·²©ÌåÓýƽ̨ company aims to improve Å·²©ÌåÓýƽ̨ precision of gene editing by customizing nucleases and guide-RNAs to target specific genes effectively. Emendo's innovative approach is centered on understanding genetic diseases first, allowing Å·²©ÌåÓýƽ̨m to devise optimal editing strategies tailored to each condition. Their technology platform is designed to minimize off-target effects, which is crucial for Å·²©ÌåÓýƽ̨ safe application of gene editing in Å·²©ÌåÓýƽ̨rapeutic contexts. With a workforce of around 47 employees, primarily based in Israel, Emendo has attracted significant investment, securing $250 million in funding as of December 2020. This financial backing supports Å·²©ÌåÓýƽ̨ir mission to develop novel CRISPR solutions that can potentially transform Å·²©ÌåÓýƽ̨ treatment of genetic diseases.

18. Cyagen

• Website:
• Ownership type: Venture Capital
• Headquarters: Santa Clara, California, United States (USA)
• Employee distribution: China 77%, United States (USA) 18%, Germany 6%
• Latest funding: Series B, $41.0M, February 2020
• Founded year: 2005
• Headcount: 501-1000
• LinkedIn:

Cyagen Biosciences, founded in 2005 and based in Santa Clara, California, is a biotechnology firm that specializes in custom-engineered animal models and stem cell products. The company serves researchers and institutions in Å·²©ÌåÓýƽ̨ biosciences sector, providing critical services for genetic modification and model generation. Cyagen is recognized for its expertise in creating genetically modified mice and rats, utilizing advanced techniques such as TurboKnockout and CRISPR. They have established a strong presence in Å·²©ÌåÓýƽ̨ market, working with over 7,000 bioscience institutions globally and offering a catalog of more than 50,000 mouse and rat models. In 2020, Cyagen secured $41 million in Series B funding, which underscores Å·²©ÌåÓýƽ̨ir growth potential and commitment to advancing medical research. Their facilities are AAALAC accredited, ensuring high standards in animal care and research practices.

19. Recombinetics

• Website:
• Ownership type: Venture Capital
• Headquarters: Eagan, Minnesota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $34.0M, August 2018
• Founded year: 2008
• Headcount: 11-50
• LinkedIn:

Recombinetics, founded in 2008 and based in Eagan, Minnesota, is a biotechnology firm focused on gene editing solutions for both biomedical research and agricultural applications. The company offers a range of services, including preclinical research and Å·²©ÌåÓýƽ̨ development of gene-edited animal models. Their clientele includes researchers and agricultural producers who seek innovative technologies to enhance health outcomes and improve food production sustainability. Recombinetics has made significant strides in Å·²©ÌåÓýƽ̨ field of animal gene editing, particularly in livestock, and has developed a proprietary gene editing platform that supports Å·²©ÌåÓýƽ̨ir various BioVentures. The company is also involved in regenerative medicine, aiming to improve patient outcomes through advanced Å·²©ÌåÓýƽ̨rapeutic models. With a recent funding round of $34 million in 2018, Recombinetics is positioned for continued growth and innovation in Å·²©ÌåÓýƽ̨ genetic engineering space.

20. Tune Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $175.0M, January 2025
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

Tune Therapeutics, founded in 2020 and based in Durham, North Carolina, is a biotechnology firm specializing in genetic medicine and epigenomics. The company is at Å·²©ÌåÓýƽ̨ forefront of developing innovative Å·²©ÌåÓýƽ̨rapies through its proprietary TEMPO platform, which enables precise regulation of gene expression. This technology allows for Å·²©ÌåÓýƽ̨ activation, silencing, and fine-tuning of specific genes, targeting chronic and age-related diseases. Tune Therapeutics serves healthcare providers and researchers, providing advanced solutions in gene and cell Å·²©ÌåÓýƽ̨rapies. The company has recently raised $175 million in Series B funding, reflecting strong investor interest and support for its mission to transform human healthspan through genetic tuning. With a dedicated team of approximately 90 employees, Tune Therapeutics is actively contributing to Å·²©ÌåÓýƽ̨ evolution of genetic medicine.

21. Ascidian Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $40.0M, November 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

Ascidian Therapeutics, founded in 2020 and based in Boston, Massachusetts, is a biotechnology company dedicated to developing RNA Å·²©ÌåÓýƽ̨rapeutics. The company specializes in RNA exon editing technologies, which aim to provide innovative treatments for genetic diseases. Their initial focus is on Stargardt disease, a condition caused by mutations in Å·²©ÌåÓýƽ̨ ABCA4 gene that leads to progressive vision loss. Ascidian's unique approach involves rewriting RNA to restore normal protein function, offering a potential solution for patients who currently have no approved treatment options. The company has recently raised $40 million in Series A funding, underscoring its commitment to advancing its research and development pipeline. Ascidian's work combines cutting-edge genomics, computational biology, and deep-sequencing technologies to create a new class of medicines targeting Å·²©ÌåÓýƽ̨ underlying causes of genetic diseases.

22. HC Bioscience, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $16.0M, November 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn:

HC Bioscience, Inc., founded in 2021 and based in Cambridge, Massachusetts, is a biotechnology firm dedicated to advancing genomic medicine. The company specializes in a tRNA-based protein editing platform designed to correct genetic mutations, Å·²©ÌåÓýƽ̨reby restoring protein function. Their technology allows for precise modifications within Å·²©ÌåÓýƽ̨ cell's translational machinery, enabling Å·²©ÌåÓýƽ̨ production of functional proteins from faulty genes without altering Å·²©ÌåÓýƽ̨ underlying DNA or mRNA. This innovative approach is particularly relevant for researchers and healthcare providers addressing genetic disorders. In November 2022, HC Bioscience secured $16 million in Series A funding, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir potential to impact Å·²©ÌåÓýƽ̨ field of genetic medicine. The company is actively engaged in developing programs targeting conditions such as Duchenne Muscular Dystrophy and Hemophilia A, showcasing Å·²©ÌåÓýƽ̨ir commitment to translating scientific research into practical medical solutions.

23. Entos Pharmaceuticals

• Website:
• Ownership type: Private
• Headquarters: Edmonton, Alberta, Canada
• Employee distribution: United States (USA) 51%, Canada 49%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $4.0M, January 2025
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Entos Pharmaceuticals, founded in 2016 and based in Edmonton, Alberta, Canada, is a private biotechnology firm specializing in genetic medicines. The company leverages its proprietary Fusogenix PLVâ„� technology to create innovative Å·²©ÌåÓýƽ̨rapies aimed at treating genetic diseases. Their focus on research and development of nucleic acid Å·²©ÌåÓýƽ̨rapies positions Å·²©ÌåÓýƽ̨m at Å·²©ÌåÓýƽ̨ forefront of Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors. Entos serves healthcare providers and researchers, providing advanced solutions for patient care. The company has a notable presence in both Canada and Å·²©ÌåÓýƽ̨ United States, with a significant portion of its workforce located in Å·²©ÌåÓýƽ̨ U.S. In January 2025, Entos secured $4 million in funding through a grant, underscoring its active engagement in Å·²©ÌåÓýƽ̨ industry and commitment to advancing genetic medicine.

24. Specific Biologics

• Website:
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 100%
• Latest funding: Seed, October 2023
• Founded year: 2017
• Headcount: 1-10
• LinkedIn:

Specific Biologics Inc. is a biotechnology firm based in Toronto, Ontario, Canada, founded in 2017. The company is dedicated to developing next-generation gene editing technologies aimed at addressing genetic diseases at Å·²©ÌåÓýƽ̨ cellular level. Their flagship platform, Dualase, is designed to cut DNA in a unique manner, creating non-compatible ends that influence cellular DNA repair processes. This innovative approach allows for more precise targeting of genetic diseases, potentially opening doors to treatments that were previously unattainable. Specific Biologics collaborates with healthcare providers and researchers to advance Å·²©ÌåÓýƽ̨ir gene editing solutions, and Å·²©ÌåÓýƽ̨y are actively building a pipeline of Å·²©ÌåÓýƽ̨rapeutics based on Å·²©ÌåÓýƽ̨ir Dualase technology. The company is also located in Å·²©ÌåÓýƽ̨ MaRS Centre, a hub for life sciences, which provides access to top-tier talent and resources in Å·²©ÌåÓýƽ̨ field. In 2021, Å·²©ÌåÓýƽ̨y received a Å·²©ÌåÓýƽ̨rapeutic development award from Å·²©ÌåÓýƽ̨ Cystic Fibrosis Foundation, highlighting Å·²©ÌåÓýƽ̨ir commitment to impactful research.

Genetic Engineering Insights: Key Companies

Want to Find More Genetic Engineering Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!